JP4285996B2 - キナゾリン誘導体 - Google Patents

キナゾリン誘導体 Download PDF

Info

Publication number
JP4285996B2
JP4285996B2 JP2002565961A JP2002565961A JP4285996B2 JP 4285996 B2 JP4285996 B2 JP 4285996B2 JP 2002565961 A JP2002565961 A JP 2002565961A JP 2002565961 A JP2002565961 A JP 2002565961A JP 4285996 B2 JP4285996 B2 JP 4285996B2
Authority
JP
Japan
Prior art keywords
group
hydrogen atom
alkyl
alkyl group
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002565961A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2002066445A1 (ja
JPWO2002066445A6 (ja
Inventor
靖典 北野
英治 河原
毅 鈴木
大輔 阿部
雅弘 中條
直子 上田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of JPWO2002066445A1 publication Critical patent/JPWO2002066445A1/ja
Publication of JPWO2002066445A6 publication Critical patent/JPWO2002066445A6/ja
Application granted granted Critical
Publication of JP4285996B2 publication Critical patent/JP4285996B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2002565961A 2001-02-21 2002-02-21 キナゾリン誘導体 Expired - Fee Related JP4285996B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001045827 2001-02-21
JP2001045827 2001-02-21
JP2001353525 2001-11-19
JP2001353525 2001-11-19
PCT/JP2002/001575 WO2002066445A1 (en) 2001-02-21 2002-02-21 Quinazoline derivatives

Publications (3)

Publication Number Publication Date
JPWO2002066445A1 JPWO2002066445A1 (ja) 2004-06-17
JPWO2002066445A6 JPWO2002066445A6 (ja) 2004-06-17
JP4285996B2 true JP4285996B2 (ja) 2009-06-24

Family

ID=26609852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002565961A Expired - Fee Related JP4285996B2 (ja) 2001-02-21 2002-02-21 キナゾリン誘導体

Country Status (10)

Country Link
US (2) US7294629B2 (enExample)
EP (1) EP1369418B1 (enExample)
JP (1) JP4285996B2 (enExample)
KR (1) KR100861486B1 (enExample)
CN (1) CN1264824C (enExample)
AT (1) ATE475652T1 (enExample)
CA (1) CA2442742A1 (enExample)
DE (1) DE60237145D1 (enExample)
TW (1) TWI309647B (enExample)
WO (1) WO2002066445A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518544A (ja) * 2011-03-04 2014-07-31 ニューゲン セラピューティクス， インコーポレイテッド アルキン置換キナゾリン化合物および使用方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
DK1667991T3 (da) 2003-09-16 2008-08-18 Astrazeneca Ab Quinazolinderivater som tyrosinkinaseinhibitorer
CN1882570B (zh) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
MXPA06003113A (es) * 2003-09-19 2006-06-20 Astrazeneca Ab Derivados de quinazolina.
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
MXPA06003341A (es) * 2003-09-25 2006-06-08 Astrazeneca Ab Derivados de quinazolina.
US20050267182A1 (en) * 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1690856A4 (en) * 2003-11-28 2007-09-05 Aveo Pharmaceuticals Inc CHINAZOLINE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF
ATE413389T1 (de) 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
AP2204A (en) 2004-05-06 2011-02-07 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides.
EP1792898A1 (en) * 2004-09-01 2007-06-06 Mitsubishi Pharma Corporation Molecular chaperone function regulator
US7947676B2 (en) 2004-12-14 2011-05-24 Astrazeneca Ab Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
CN101163684B (zh) 2005-02-23 2012-08-29 盐野义制药株式会社 具有酪氨酸激酶抑制作用的喹唑啉衍生物
KR20070107151A (ko) * 2005-02-26 2007-11-06 아스트라제네카 아베 티로신 키나제 억제제로서의 퀴나졸린 유도체
JP4993205B2 (ja) * 2005-03-30 2012-08-08 塩野義製薬株式会社 チロシンキナーゼ阻害作用を有するピリミジン誘導体
US7820683B2 (en) 2005-09-20 2010-10-26 Astrazeneca Ab 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
AU2007224162A1 (en) * 2006-03-03 2007-09-13 Aveo Pharmaceuticals, Inc. Processes for synthesizing 7-alkynyl-4-aminoquinazolines and a related intermediate
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008095847A1 (de) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
MX2012010557A (es) * 2010-03-16 2012-10-05 Merck Patent Gmbh Morfolinilquinazolinas.
CN102918029B (zh) * 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
AU2013207712B2 (en) 2012-01-13 2017-08-31 Acea Biosciences Inc. Heterocyclic compounds and uses as anticancer agents.
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
CN103254143B (zh) * 2013-04-26 2015-10-07 浙江工业大学 4-[4-(2-二乙氨基乙酰氨基)苯胺基]-6-取代喹唑啉类化合物及制备和应用
TWI609012B (zh) 2013-04-28 2017-12-21 廣東東陽光藥業有限公司 氨基喹唑啉類衍生物及其鹽和使用方法
KR102173433B1 (ko) 2013-07-11 2020-11-04 에이시아 바이오사이언시스 인코포레이티드. 키나아제 억제제로써의 피리미딘 유도체
WO2017059702A1 (en) 2015-10-09 2017-04-13 Acea Biosciences, Inc Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
US10953016B2 (en) * 2017-01-30 2021-03-23 Shionogi & Co., Ltd. Solid dosage form containing quinazoline derivative
US11498922B2 (en) 2017-04-07 2022-11-15 ACEA Therapeutics, Inc. Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide
CN110577514B (zh) * 2018-06-08 2022-07-05 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
WO2019233459A1 (zh) * 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
CN119390683A (zh) * 2019-08-15 2025-02-07 黑钻治疗公司 炔基喹唑啉化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134236B2 (ja) 1992-01-30 2001-02-13 株式会社林原生物化学研究所 α−グリコシル−Ｌ−アスコルビン酸高含有物の製造方法とその製造のための分離システム
JP2994165B2 (ja) 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6251912B1 (en) * 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
NZ522568A (en) * 2000-06-22 2004-12-24 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
EP1690856A4 (en) * 2003-11-28 2007-09-05 Aveo Pharmaceuticals Inc CHINAZOLINE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518544A (ja) * 2011-03-04 2014-07-31 ニューゲン セラピューティクス， インコーポレイテッド アルキン置換キナゾリン化合物および使用方法
US11524956B2 (en) 2011-03-04 2022-12-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use

Also Published As

Publication number Publication date
EP1369418A4 (en) 2005-09-14
US7294629B2 (en) 2007-11-13
KR20030086269A (ko) 2003-11-07
KR100861486B1 (ko) 2008-10-02
JPWO2002066445A1 (ja) 2004-06-17
ATE475652T1 (de) 2010-08-15
EP1369418A1 (en) 2003-12-10
TWI309647B (enExample) 2009-05-11
US20040116422A1 (en) 2004-06-17
CN1492860A (zh) 2004-04-28
DE60237145D1 (de) 2010-09-09
EP1369418B1 (en) 2010-07-28
US20070265260A1 (en) 2007-11-15
CN1264824C (zh) 2006-07-19
CA2442742A1 (en) 2002-08-29
WO2002066445A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
KR100861486B1 (ko) 퀴나졸린 유도체
JPWO2002066445A6 (ja) キナゾリン誘導体
EP1110953B1 (en) Quinazoline derivatives
JP6457623B2 (ja) ２，４−二置換７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法および医薬における使用
US6384223B1 (en) Substituted quinazoline derivatives
CA2218945C (en) 4-aminoquinazoline derivatives
US5834463A (en) Condensed heterocyclic compounds, their production and use
KR20220108070A (ko) 신규 오로라 키나아제 억제제 및 이의 용도
EP2740729B1 (en) Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament
PL218769B1 (pl) Podstawione 3-cyjanochinoliny lub ich farmaceutycznie dopuszczalne sole jako inhibitory białkowych kinaz tyrozynowych
EP1100788B1 (en) Substituted quinazoline derivatives
CN101638383B (zh) 喹啉衍生物及其药物组合物和用途
JPH1180131A (ja) エチニルピリミジン誘導体
EP0529386A1 (en) Dibenz[B,F][1,4]oxazepin-11(10H)-ones for multidrug resistance reversing agents
JP2007506744A (ja) 抗癌剤としての６−［（置換）フェニル］トリアゾロピリミジン類
ITMI20082336A1 (it) Composti inibitori irreversibili di egfr con attivita' antiproliferativa
US20050075354A1 (en) Complexes of E-2-Methoxy-N(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinzazolin-6-YL}-allyl)-acetamide, their method of production, and use
US6680326B2 (en) Polycyclic compounds
Liu et al. Synthesis and cytotoxicity studies of new cryptophycin analogues
EP4306518A1 (en) Novel pyrimidine derivative showing inhibition effect on growth of cancer cells
CN103554091B (zh) 喹唑啉衍生物及其制备方法和用途
WO2023010354A1 (zh) 一种具有egfr抑制活性的小分子化合物及其制备方法与应用
ZA200502510B (en) Oxygenate treatment of dewaxing catalyst for greatyield of dewaxed product.
HK1244794A1 (en) Cyanoquinoline derivatives
HK1082499A (en) Complexes of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide, their method of production, and use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050221

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20071102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090310

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090324

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120403

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120403

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120403

Year of fee payment: 3

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120403

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120403

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees